SCHEMBL18212652

SCHEMBL18212652

CC(C)C(=O)[C@]1(O)CC[C@@H](C(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
GRM2 Q14416 2/20 0.38
GRM3 Q14832 2/20 0.38
GRM4 Q14833 2/20 0.38
TSHR P16473 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
ALOX15 P16050 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRM5 P41594 1/20 0.38
MTOR P42345 1/20 0.38
GRM1 Q13255 1/20 0.38
PLCB1 Q9NQ66 1/20 0.38
APLNR P35414 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18212650 0.80 GRM2 (0.36) LMNAGRM2GRM3GRM4TSHR
SCHEMBL16892298 0.78 TSHR (0.41) LMNAGRM2GRM3GRM4TSHR
SCHEMBL18215826 0.78 TSHR (0.41) LMNAGRM2GRM3GRM4TSHR
SCHEMBL11927964 0.78 MEN1 (0.35) CYP2C19
SCHEMBL16750082 0.77 TSHR (0.39) LMNAGRM2GRM3GRM4TSHR
SCHEMBL6913975 0.77 SMYD3 (0.32)
SCHEMBL16000454 0.77 TSHR (0.39) LMNAGRM2GRM3GRM4TSHR
SCHEMBL16750080 0.77 TSHR (0.39) LMNAGRM2GRM3GRM4TSHR
SCHEMBL888643 0.77
SCHEMBL21242166 0.73 LMNA (0.41) LMNAGRM2GRM3GRM4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180002358-A1 TRICYCLIC SULFONES AS ROR GAMMA MODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-01-04 US disclosed
US-9815859-B2 Tricyclic sulfones as RORγ modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2017-11-14 US disclosed
US-20160326195-A1 TRICYCLIC SULFONES AS RORy MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002358-A1 TRICYCLIC SULFONES AS ROR GAMMA MODULATORS RORC, RORB, RORA LMNA 3931/4885GRM2 670/4885GRM3 456/4885
US-20160326195-A1 TRICYCLIC SULFONES AS RORy MODULATORS RORB, RORC, RORA LMNA 4243/4885GRM2 601/4885GRM3 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.